NewAmsterdam Pharma (NAMS) EBIT Margin (2023 - 2026)
NewAmsterdam Pharma (NAMS) recorded EBIT Margin of -1752.61% in Q2 2026, down 1566.48 percentage points from -186.13% a year earlier but up 169.10 percentage points from the prior quarter.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) EBIT Margin (2023 - 2026) Analysis & Trends
On a TTM basis, NewAmsterdam Pharma's EBIT Margin came in at -3432.20% as of Jun 30, 2026, down 3162.24 percentage points year-over-year; for FY2025, it came in at -1002.90%, down 615.99 percentage points from FY2024.
- Annual EBIT Margin has a three-year change of -933.56 percentage points (FY2022 to FY2025).
- Across earlier years, EBIT Margin came in at -386.91% in FY2024 (+911.65 pp), -1298.56% in FY2023 (-1229.22 pp) and -69.34% in FY2022.
- Quarterly EBIT Margin has ranged from -206187.50% in Q4 2025 to -85.89% in Q3 2024 over the past five years.
- On a year-over-year basis, EBIT Margin rose in five of the last eight quarters, with an average year-over-year change of -26424.37 percentage points.
- Peak year-over-year performance for EBIT Margin in the last five years was a gain of 6021.93 percentage points in Q4 2024, against a drop of 205849.03 percentage points in Q4 2025 at the low end.
- Per Business Quant, the preceding three quarters came in at -1921.71% (Q1 2026), -206187.50% (Q4 2025) and -15845.69% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 28.37% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 37.40% |
| 10 | NewAmsterdam Pharma | 2.77 Bn | 2.77 Bn | - | -1,752.61% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,752.61% |
| Mar 31, 2026 | -1,921.71% |
| Dec 31, 2025 | -206,187.50% |
| Sep 30, 2025 | -15,845.69% |
| Jun 30, 2025 | -186.13% |
| Mar 31, 2025 | -2,314.47% |
| Dec 31, 2024 | -338.47% |
| Sep 30, 2024 | -85.89% |
| Jun 30, 2024 | -2,306.93% |
| Mar 31, 2024 | -3,960.17% |
| Dec 31, 2023 | -6,360.40% |
| Sep 30, 2023 | -1,685.07% |
| Jun 30, 2023 | -2,474.20% |
| Mar 31, 2023 | -461.85% |
API Access
NewAmsterdam Pharma EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=NAMS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "NAMS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=NAMS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();